Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

BACKGROUND: Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was perfor...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hottinger, A F, Aissa, A B, Espeli, V, Squiban, D, Dunkel, N, Vargas, M I, Hundsberger, T, Mach, N, Schaller, K, Weber, D C, Bodmer, A, Dietrich, P-Y
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2014
Gaiak:
Clinical Study
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4037825/
https://ncbi.nlm.nih.gov/pubmed/24786603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.209
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak